Evidence map›Paper›PMID 30242748›Full record

ArticleInflammopharmacology2019

IL-1β, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients.

Yufang Liu, Guifang Qin, Zudong Meng, Tianping Du, Xiaolan Wang, Yong Tang, Jingjing Cao

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammopharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Predictors of clinical response to biologics in psoriasis: A systematic review and meta-analysis.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026
    Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yufang LiuDepartment of Dermatology, The People's Hospital of Shiyan, The Affiliated People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 442000, China.
Guifang QinDepartment of Dermatology, The People's Hospital of Shiyan, The Affiliated People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 442000, China.
Zudong MengDepartment of Dermatology, The People's Hospital of Shiyan, The Affiliated People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 442000, China. mengzudong3320@126.com.ORCID http://orcid.org/0000-0002-2158-6368
Tianping DuDepartment of Neurosurgery, The People's Hospital of Shiyan, The Affiliated People's Hospital, Hubei University of Medicine, Shiyan, China.
Xiaolan WangDepartment of Dermatology, The People's Hospital of Shiyan, The Affiliated People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 442000, China.
Yong TangDepartment of Rehabilitation, Sinopharm Dong Feng General Hospital, The Affiliated Dong Feng Hospital, Hubei University of Medicine, Shiyan, China.
Jingjing CaoDepartment of Dermatology, The People's Hospital of Shiyan, The Affiliated People's Hospital, Hubei University of Medicine, 39 Middle Chaoyang Road, Shiyan, 442000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThis study aimed to explore the correlation of circulating inflammatory cytokines' levels with treatment response to etanercept (ETN) treatment in psoriasis patients.

methods97 moderate-to-severe plaque-psoriasis patients were continuously recruited in this prospective cohort study, and all patients received ETN treatment. Serum samples were collected before and at 6 months (M6) after treatment, and nine inflammatory cytokines expressions were detected by enzyme-linked immuno sorbent assay. Psoriasis Area and Severity Index (PASI) score was evaluated at baseline (M0), 1 month (M1), 3 months (M3) and M6 after treatment, and the corresponding PASI 75/90 responses' rates were calculated.

resultsTumor necrosis factor-alpha (TNF-α), interleukin (IL)-1β, IL-6, IL-12, IL-17A, IL-22, IL-23, and IL-32 levels were reduced, while IL-10 level was elevated at M6 after ETN treatment compared to baseline. PASI 75/90 responses' rates to ETN were 69.1 and 38.1% at M6, respectively. IL-1β and IL-17A levels were elevated in PASI 75-response patients compared to PASI 75 non-response patients, while IL-17A level was also increased in PASI 90-response patients compared to PASI 90 non-response patients. Multivariate logistic regression revealed that IL-1β, IL-17A and combined phototherapy during study predicted higher, while previous systemic biologic treatment predicted lower PASI 75 response to ETN independently. In addition, IL-17A independently predicted higher PASI 90 response to ETN as well.

conclusionsIL-1β, IL-17A, and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to ETN independently in psoriasis patients.

Indexed as

EtanerceptFemaleHumansInterleukin-17Interleukin-1betaMaleMiddle AgedPhototherapyProspective StudiesPsoriasisSeverity of Illness IndexTreatment OutcomeTumor Necrosis Factor-alphaEtanerceptIL17A protein, humanInterleukin-17Interleukin-1betaTumor Necrosis Factor-alphaInflammatory cytokinesPASI scorePsoriasisTreatment response

Identifiers

PMID30242748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.